Patent SG-11201810333U-A (SG)
Title: Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders
Inventor: WEISS MICHAEL
IPC: A61K31/416
Filed: 2017-05-26
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101/110 111010101111101011111 0 0111111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2017/205843 Al 30 November 2017 (30.11.2017) WIPO I PCT (51) International Patent Classification: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, A61K 31/00 (2006.01) A61K 31/4155 (2006.01) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, A61K 39/395 (2006.01) A61K 31/416 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/US2017/034855 Published: (22) International Filing Date: — with international search report (Art. 21(3)) 26 May 2017 (26.05.2017) — with amended claims (Art. 190)) — with sequence listing part of description (Rule 5.2(a)) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/342,822 27 May 2016 (27.05.2016) US (71) Applicants: TG THERAPEUTICS, INC. [US/US]; 2 Gansevoort Street, 9th Floor, New York, NY 10014 (US). RHIZEN PHARMACEUTICALS SA [CH/CH]; Fritz Courvoisier 40, 2300 La Chaux de Fonds (CH). LABO- RATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES [FR/FR]; 3 Avenue des Tropiques, 91940 Les Ulis (FR). Inventors: WEISS, Michael, S.; c/o TG Therapeutics, Inc., 2 Gansevoort Street, 9th Floor, New York, NY 10014 (US). = (72) MISKIN, Hari, P.; c/o TG Therapeutics, Inc., 2 Gansevoort = — Street, 9th Floor, New York, NY 10014 (US). SPORTEL- LI, Peter; c/o TG Therapeutics, Inc., 2 Gansevoort Street, 9th Floor, New York, NY 10014 (US). =_ Agent: STEFFE, Eric, K. et al.; Sterne, Kessler, Goldstein (74) & Fox P.L.L.C, 1100 New York Avenue, NW, Washington, DC 20005 (US). = Designated States (unless otherwise indicated, for every = (81) = kind of national protection available): AE, AG, AL, AM, = AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, = DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, = = PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, = — SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, = TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every (84) = kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, — - UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, M 71' (54) Title: COMBINATION OF ANTI-CD20 ANTIBODY, P13 KINASE-DELTA SELECTIVE INHIBITOR, AND BTK INHIBI- in c:::: ) TOR TO TREAT B-CELL PROLIFERATIVE DISORDERS el ----. (57) : Methods for inhibiting proliferation of a B-cell population are provided comprising administering a combination of IN Il agents, comprising: (i) at least one P13K-delta selective inhibitor; (ii) at least one anti-CD20 antibody; and (iii) at least one Bruton's © tyrosine kinase (BTK) inhibitor. Methods for treating B-cell proliferative disorders, such as B-cell hematological malignancies, as well N as kits for carrying out the claimed methods, are also provided. 0